Sponsor:
Aventusoft, LLC.
Code:
NCT06567795
Conditions
Diabetes Mellitus Type 2
Cardiovascular Diseases
Coronary Artery Disease
Cerebrovascular Disease
Peripheral Artery Disease
Eligibility Criteria
Sex: All
Age: 40+
Healthy Volunteers: Not accepted
Interventions
Hemotag
Brief summary:
Conditions
Diabetes Mellitus Type 2
Cardiovascular Diseases
Coronary Artery Disease
Cerebrovascular Disease
Peripheral Artery Disease
Study ID
NCT06567795
Start date
Mar 14, 2024
Status verified date
Aug, 2024
Completion date
Mar 18, 2027
Anticipated
Primary completion date
Mar 18, 2026
Anticipated
Eligibility Criteria
Sex: All
Age: 40+
Healthy Volunteers: Not accepted
Enrollment
189 participants
Anticipated
Arms
HEMOTAG with Standard of Care in DM patients
Interventions
Hemotag
Primary outcome measure
Central contacts
Locations
Metabolic Research Institute, Inc
Recruiting
West Palm Beach, Florida, United States, 33401'
Contacts
Principal Investigator:
Barry Horowitz, MD
Sponsor
Aventusoft, LLC.
Last update posted
Aug 23, 2024
Last verified
Aug, 2024
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Aventusoft, LLC. on 2024-08-23.